The virus may have cleared, but the inflammation rages on
For over a century, dengue fever has been understood but never truly answered — a disease identified in the early 1900s, yet still met at the clinic with little more than patience and pain relief. Now, for the first time, two drug candidates are entering human trials through the Dengue Alliance, a partnership spanning Brazil, India, Malaysia, and Thailand, offering the possibility that medicine may finally close the distance between knowing a disease and curing it. The urgency is sharpened by a warming world that is carrying dengue's mosquito vector into new territories, transforming what was once dismissed as a distant problem into a shared one.
- Dengue has infected and killed for generations with no direct treatment — every patient who walks into a clinic still faces the same answer: wait, manage the symptoms, and hope.
- The disease's cruelest twist is that its most dangerous phase — an inflammatory storm that causes plasma leakage and circulatory shock — can rage even after the virus itself has cleared, meaning a simple antiviral may not be enough.
- The Dengue Alliance is now running parallel tracks, testing both a monoclonal antibody already in phase III trials in India and an oral pill still under negotiation, with Malaysia's Hospital Raja Permaisuri Bainun in Ipoh serving as a key trial site.
- Climate change is expanding dengue's reach beyond its traditional tropical boundaries, raising the stakes for countries that once considered themselves safe and making affordability of any new treatment a non-negotiable priority.
- Prevention holds the line for now — mosquito control, two available vaccines, and community vigilance — but the alliance is clear that treatment and prevention must advance together, because neither is sufficient alone.
For more than a century, dengue fever has circled the globe without a cure. The virus was identified in the early 1900s, yet when a patient arrives at a clinic with dengue today, there is still no drug to kill it — only fever management and time, as the virus runs its roughly ten-day course.
The gap between knowledge and treatment is both biological and practical. Antivirals must be given early to work, but patients often wait before seeking care, and fever alone is common to dozens of illnesses. By the time a diagnosis is confirmed, the treatment window may already be closing. Worse still, dengue's most dangerous complications — plasma leakage, circulatory shock, sometimes death — are not caused by the virus itself but by the body's own inflammatory response, which can spiral long after the virus has cleared.
For decades, dengue was seen as a problem belonging to poor and tropical nations, without the resources to fund expensive drug development. Climate change is rewriting that assumption, pushing the Aedes aegypti mosquito into new territories and making dengue a concern for an expanding share of the world.
In 2022, the Dengue Alliance formed between the Drugs for Neglected Diseases initiative and health institutions in Brazil, India, Malaysia, and Thailand. The alliance is pursuing two strategies simultaneously: antivirals that target the virus directly, and host-directed therapies designed to prevent the immune system from turning on itself. Two candidates are now advancing. A monoclonal antibody developed by the Serum Institute is already in phase III trials in India and will expand to Malaysia, Brazil, and Thailand — with Hospital Raja Permaisuri Bainun in Ipoh serving as Malaysia's primary site. Administered intravenously over about an hour, it will be available to patients aged five and older, with health clinics referring patients to hospitals for treatment. An oral pill remains under negotiation, with researchers still weighing two options before committing to phase III.
The alliance has made affordability and accessibility central commitments, recognizing that a treatment unreachable by the countries most affected would be no treatment at all. In the meantime, prevention remains essential — eliminating standing water, staying alert in hotspot areas, and vaccination, including TAK-003, available in Malaysia's private sector since 2024. The work of cure and prevention moves forward together, each necessary, neither complete without the other.
For more than a century, dengue fever has circled the globe without a cure. Doctors know the virus well enough—it was identified in the early 1900s, though the disease itself appears in Chinese medical texts from the Jin Dynasty, nearly 1,600 years ago. Yet when a patient walks into a clinic with dengue, there is still no drug to kill it. Treatment amounts to managing fever, pain, and the body's own response while the virus runs its course, usually lasting about ten days from infection, though symptoms typically emerge only four to five days in.
This gap between knowing a disease and treating it exists for reasons both biological and practical. The dengue virus moves fast through the body, which means any antiviral drug must be given early to work at all. But people rarely seek care the moment they fall ill. They wait. They hope the fever will break on its own. By the time they see a doctor, half the window for direct treatment has already closed. Doctors themselves face a diagnostic puzzle—fever is common to dozens of illnesses, and dengue's other symptoms can be vague enough to mask the true culprit.
There is another layer of complexity that makes dengue particularly difficult to treat. Some of the disease's worst complications do not come from the virus itself, but from the body's fight against it. When the immune system launches its response, it can spiral into what researchers call an inflammatory storm. The virus may have already cleared from the bloodstream, but the inflammation rages on, causing plasma to leak from blood vessels, sending patients into circulatory shock, sometimes to death. A drug that simply kills the virus will not stop this cascade once it has begun.
For decades, dengue remained a problem of poor and middle-income countries in tropical regions, places without the resources to fund the expensive research needed to develop new medicines. The disease was seen as someone else's problem. But climate change is shifting the geography of dengue's main mosquito vector, Aedes aegypti, northward and into new territories. A more connected world means more travelers carrying the virus across borders. The calculus has changed.
In 2022, the Dengue Alliance formed as a partnership between the Drugs for Neglected Diseases initiative and health institutions in Brazil, India, Malaysia, and Thailand. The alliance is pursuing two parallel strategies: developing antivirals that target the virus itself, and what researchers call host-directed therapies—drugs that calm the inflammatory response and prevent the body from turning on itself. The goal is not just to save lives, but to reduce the duration of illness, to let people return to work and school, to ease the economic burden that dengue places on individuals and families.
Two drug candidates are now moving toward human testing. The first is a monoclonal antibody already in phase III trials in India, developed by the Serum Institute. Following an agreement between the Serum Institute and the Drugs for Neglected Diseases initiative, this antibody will be tested in Malaysia, Brazil, and Thailand as well. In Malaysia, the Health Ministry is coordinating the trials, with Hospital Raja Permaisuri Bainun in Ipoh as the primary site. The treatment requires intravenous administration—about an hour in a hospital chair—and will be available to dengue patients age five and older. Health clinics will refer patients to hospitals for the infusion, creating a pathway from community care to specialized treatment.
The second candidate is an oral pill, a drug that could be taken at home, but negotiations with manufacturers are still underway. Researchers are weighing two options and have not yet chosen which to advance to phase III trials. Both approaches reflect a hard-won understanding: there is no single solution to dengue. The alliance is also committed to ensuring that whatever emerges from these trials will be affordable, accessible, and practical for the countries that need it most.
Meanwhile, prevention remains the first line of defense. The Aedes mosquito breeds in tiny pools of standing water—a bottle cap's worth is enough. Keeping homes and neighborhoods clean, eliminating breeding sites, and staying alert in dengue hotspots can prevent infection before it starts. Two vaccines are now available: one called TAK-003, available in Malaysia's private sector since 2024 at a cost of roughly 300 to 500 ringgit for two doses, with nearly 29,000 doses administered by early 2026. Another vaccine, developed in Brazil, has been temporarily suspended while health authorities investigate two deaths possibly linked to it. The work of treatment and prevention moves forward in parallel, each essential, neither sufficient alone.
Notable Quotes
Some complications are caused by the virus, others by the inflammatory response the body directs at the virus, which ends up being damaging— Dr. Andre Siqueira, Drugs for Neglected Diseases initiative Dengue Global Programme head
Our intention is to have an affordable treatment, easy access and one that is user-friendly— Datuk Dr. Nor Fariza Ngah, Health Ministry deputy director-general
The Hearth Conversation Another angle on the story
Why has it taken so long to develop a dengue treatment when we've known about the disease for centuries?
The virus itself is only in the body for about ten days, and people don't usually seek care until the fever starts—which is already four or five days in. So the window to treat the active infection is incredibly narrow. But there's something deeper: some of the worst damage comes not from the virus, but from the body's own immune response. You can't just kill the virus and expect the patient to recover.
So you're saying the body is fighting itself?
Exactly. Once the immune system launches its inflammatory response, it can become a storm. Plasma leaks from blood vessels, the patient goes into shock. By then, the virus may already be gone. A drug that only targets the virus won't stop that cascade.
That sounds like you need two different drugs.
That's the insight behind the Dengue Alliance's strategy. They're pursuing antivirals to stop the virus early, and host-directed therapies to calm the inflammatory response. The hope is eventually to combine them, to hit the disease from both angles.
Why is this happening now, after all these years?
Climate change is expanding where the dengue mosquito can survive. More countries are at risk. And dengue is no longer seen as just a problem for poor tropical nations—it's becoming a global threat. That changes the investment calculus.
What about the trials starting next year—are they likely to succeed?
There's real hope. One candidate is a monoclonal antibody already in phase III trials in India. The other is an oral pill still being negotiated. But success isn't just about efficacy. The alliance is committed to making whatever emerges affordable and accessible. That's as important as the drug itself.
And if these trials fail?
Then the work continues. But for the first time, there's coordinated effort across multiple countries, real resources, and a clear understanding of what dengue actually does to the body. That's new.